JP2021519065A5 - - Google Patents

Info

Publication number
JP2021519065A5
JP2021519065A5 JP2020551357A JP2020551357A JP2021519065A5 JP 2021519065 A5 JP2021519065 A5 JP 2021519065A5 JP 2020551357 A JP2020551357 A JP 2020551357A JP 2020551357 A JP2020551357 A JP 2020551357A JP 2021519065 A5 JP2021519065 A5 JP 2021519065A5
Authority
JP
Japan
Prior art keywords
bone
nucleic acids
inhibitory nucleic
nucleic acid
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020551357A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519065A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023759 external-priority patent/WO2019183605A1/en
Publication of JP2021519065A publication Critical patent/JP2021519065A/ja
Publication of JP2021519065A5 publication Critical patent/JP2021519065A5/ja
Pending legal-status Critical Current

Links

JP2020551357A 2018-03-23 2019-03-22 骨障害を処置するための遺伝子治療法 Pending JP2021519065A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862647595P 2018-03-23 2018-03-23
US62/647,595 2018-03-23
US201962799843P 2019-02-01 2019-02-01
US62/799,843 2019-02-01
PCT/US2019/023759 WO2019183605A1 (en) 2018-03-23 2019-03-22 Gene therapeutics for treating bone disorders

Publications (2)

Publication Number Publication Date
JP2021519065A JP2021519065A (ja) 2021-08-10
JP2021519065A5 true JP2021519065A5 (cg-RX-API-DMAC7.html) 2022-03-30

Family

ID=67986628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020551357A Pending JP2021519065A (ja) 2018-03-23 2019-03-22 骨障害を処置するための遺伝子治療法

Country Status (8)

Country Link
US (2) US12194108B2 (cg-RX-API-DMAC7.html)
EP (2) EP4169576A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021519065A (cg-RX-API-DMAC7.html)
KR (1) KR20200135433A (cg-RX-API-DMAC7.html)
CN (1) CN112368051A (cg-RX-API-DMAC7.html)
AU (1) AU2019237514A1 (cg-RX-API-DMAC7.html)
CA (1) CA3094217A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019183605A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4169576A1 (en) 2018-03-23 2023-04-26 University of Massachusetts Gene therapeutics for treating bone disorders
US20240002844A1 (en) * 2020-08-19 2024-01-04 University Of Massachusetts Development of novel gene therapeutics for inflammation-induced bone loss
CN113913463B (zh) * 2021-09-19 2023-08-18 郭保生 抑制sost基因表达的重组质粒及其骨靶向重组腺相关病毒与应用
US20250388925A1 (en) * 2021-11-04 2025-12-25 University Of Massachusetts Wnt-modulating gene silencers as bone anabolic therapy for osteoporosis and critical-sized bone defect
WO2024220463A2 (en) * 2023-04-17 2024-10-24 University Of Massachusetts Aav5 capsid with non-canonical amino acid incorporation and uses thereof
CN118453845B (zh) * 2024-05-30 2025-02-14 山东第一医科大学附属省立医院(山东省立医院) 提高dj-1基因表达量的试剂在制备抗血管钙化药物中的应用
CN120535659B (zh) * 2025-07-29 2025-10-17 苏州大学 一种骨靶向的三聚体蛋白及其制备方法与应用
CN121249673B (zh) * 2025-12-05 2026-04-07 北京大学第三医院(北京大学第三临床医学院) 一种靶向ybx1的骨关节炎治疗与诊断产品及应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5252334A (en) 1989-09-08 1993-10-12 Cygnus Therapeutic Systems Solid matrix system for transdermal drug delivery
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US5942496A (en) 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5697899A (en) 1995-02-07 1997-12-16 Gensia Feedback controlled drug delivery system
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US5783208A (en) 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
US5779708A (en) 1996-08-15 1998-07-14 Cyberdent, Inc. Intraosseous drug delivery device and method
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
US6177403B1 (en) 1996-10-21 2001-01-23 The Trustees Of The University Of Pennsylvania Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
ES2639020T3 (es) 1998-11-27 2017-10-25 Ucb Pharma S.A. Composiciones y métodos para incrementar la mineralización de la substancia ósea
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) * 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
US7972593B2 (en) 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
EP1874811B1 (en) 2005-04-15 2012-06-13 President and Fellows of Harvard College Methods for modulating bone formation and mineralization by modulating KRC activity
US7816140B2 (en) * 2005-06-14 2010-10-19 The United States Of America As Represented By The Department Of Veterans Affairs Composition and methods for osteogenic gene therapy
US8859752B2 (en) 2006-04-18 2014-10-14 The Trustees Of The University Of Pennsylvania SIRNA-based therapy of Fibrodyplasia Ossificans Progressiva (FOP)
US8298818B2 (en) 2006-04-28 2012-10-30 University Of Florida Research Foundation, Inc. Self-complementary adeno-associated virus having a truncated CMV-chicken β-actin promoter
CA2671437A1 (en) 2006-10-31 2008-05-29 University Of Rochester Targeted delivery of therapeutic agents with lyophilized matrices
WO2008127587A2 (en) 2007-04-11 2008-10-23 Merck & Co., Inc. Isolated nucleic acid molecules corresponding to micro rna 145 (mirna-145) and their use in treating colon cancer
CN102438580B (zh) * 2009-02-06 2015-06-17 加利福尼亚大学董事会 钙结合剂诱导毛发生长和/或甲生长
WO2011088163A1 (en) * 2010-01-14 2011-07-21 President And Fellows Of Harvard College Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
DK2561073T3 (en) 2010-04-23 2016-12-12 Univ Massachusetts Aav vectors targeted to central nervous system and methods of use thereof
KR101869077B1 (ko) 2010-05-03 2018-06-22 더 텍사스 에이 & 엠 유니버시티 시스템 눈 손상 및 질환 치료용 성체 줄기 세포/전구 세포 및 줄기 세포 단백질
EP3838922A1 (en) 2010-10-27 2021-06-23 Amgen Inc. Dkk1 antibodies and methods of use
ES2632212T3 (es) 2011-08-04 2017-09-11 Yeda Research And Development Co. Ltd. miR-135 y composiciones que lo comprenden para el tratamiento de afecciones médicas asociadas con la serotonina
US20130136729A1 (en) 2011-11-11 2013-05-30 University of Virginia Patent Foundation, d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for targeting and treating diseases and injuries using adeno-associated virus vectors
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
WO2014005314A1 (zh) * 2012-07-05 2014-01-09 香港中文大学 基于小核酸药物成骨治疗的骨靶向递送系统及其制备方法
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
DE102013111099B4 (de) 2013-10-08 2023-11-30 Eberhard Karls Universität Tübingen Medizinische Fakultät Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
JP7026440B2 (ja) 2014-05-28 2022-02-28 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ハイブリッドtRNA/プレmiRNA分子および使用方法
WO2016065001A1 (en) * 2014-10-21 2016-04-28 University Of Massachusetts Recombinant aav variants and uses thereof
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
CA3081058C (en) * 2015-01-16 2024-02-20 Academia Sinica Linker units and their uses in configuring pharmaceutical molecules
IL310375B2 (en) * 2015-01-20 2025-05-01 Genzyme Corp Analytical ultracentrifugation for characterization of recombinant viral particles
CA3255657A1 (en) 2015-02-10 2025-12-01 Genzyme Corporation VARIANT RNAi
EP3256170B1 (en) 2015-02-13 2020-09-23 University of Massachusetts Compositions and methods for transient delivery of nucleases
US11046955B2 (en) 2015-04-24 2021-06-29 University Of Massachusetts Modified AAV constructs and uses thereof
WO2016183297A1 (en) * 2015-05-12 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
JP2018537983A (ja) 2015-12-10 2018-12-27 ウニヴェルズィテート・フューア・ボーデンクルトゥーア・ウィーン 骨折および骨障害の診断および治療のための組成物および方法
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
US20190216943A1 (en) * 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
CA3034089A1 (en) 2016-08-18 2018-02-22 The Regents Of The University Of California Crispr-cas genome engineering via a modular aav delivery system
JP2020500217A (ja) 2016-10-27 2020-01-09 セレクセルSelexel 癌治療用の新しい二本鎖オリゴヌクレオチド
WO2018150271A1 (en) 2017-02-17 2018-08-23 Lonza Ltd. Mammalian cells for producing adeno-associated viruses
EP4169576A1 (en) 2018-03-23 2023-04-26 University of Massachusetts Gene therapeutics for treating bone disorders
JP2022520148A (ja) 2018-12-06 2022-03-29 アークトゥラス・セラピューティクス・インコーポレイテッド 修飾タンパク質および関連の処置方法
US12428484B2 (en) 2018-12-06 2025-09-30 Alexion Pharmaceuticals, Inc. Anti-ALK2 antibodies and uses thereof
CN111407758A (zh) 2019-01-08 2020-07-14 上海中医药大学附属龙华医院 斑蝥素作为miR-214-3p/Wnt/β-Catenin信号通路抑制剂防治骨肉瘤的用途
JP7858532B2 (ja) 2020-01-10 2026-05-14 ダイン セラピューティクス,インコーポレーテッド 筋肉標的複合体および筋肉の健康に関連する遺伝子のモジュレーションのためのその使用
BR112022019304A2 (pt) 2020-03-31 2022-12-06 Univ Massachusetts Variantes de capsídeo de aav e usos das mesmas
US20240002844A1 (en) 2020-08-19 2024-01-04 University Of Massachusetts Development of novel gene therapeutics for inflammation-induced bone loss
EP4255457A4 (en) 2020-12-03 2025-05-21 University of Massachusetts DEVELOPMENT OF NEW GENE THERAPEUTIC AGENTS FOR FIBRODYSPLASIA OSSIFICANS PROGRESSIVA
WO2022221581A1 (en) 2021-04-15 2022-10-20 Mammoth Biosciences, Inc. Programmable nucleases and methods of use
EP4366774A4 (en) 2021-07-09 2025-11-19 Dyne Therapeutics Inc MUSCLE TARGETTING COMPLEXES AND THEIR USES FOR MODULATING GENES ASSOCIATED WITH MUSCLE HEALTH

Similar Documents

Publication Publication Date Title
JP7395550B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
JP2022508182A5 (cg-RX-API-DMAC7.html)
US20240197918A1 (en) Tissue-targeted modified aav capsids and methods of use thereof
JP2020019772A5 (cg-RX-API-DMAC7.html)
JP2022512726A5 (cg-RX-API-DMAC7.html)
JP2020528734A5 (cg-RX-API-DMAC7.html)
RU2017115477A (ru) Полинуклеотиды aadc для лечения болезни паркинсона
JP2020519284A5 (cg-RX-API-DMAC7.html)
TW202005978A (zh) 新穎肝靶向腺相關病毒載體
RU2018116076A (ru) Модифицированные гены атаксии фридрейха и векторы для генной терапии
JP2017509632A5 (cg-RX-API-DMAC7.html)
JP2007507223A5 (cg-RX-API-DMAC7.html)
US12077772B2 (en) Transgene cassettes, AAV vectors and AAV viral vectors for the expression of human codon-optimized SLC6A1
US20240269161A1 (en) Methods and compositions for tau reduction gene therapy
JP2023138527A (ja) スペーサーを含む核酸分子およびその使用の方法
JP2017529395A5 (cg-RX-API-DMAC7.html)
JP2024512483A5 (cg-RX-API-DMAC7.html)
JP2023537358A5 (cg-RX-API-DMAC7.html)
AR123948A1 (es) ANTICUERPOS ANTI-TNF-a VECTORIZADOS PARA INDICACIONES OCULARES
US20250207126A1 (en) Modified muscle-specific promoters
JP2025513785A5 (cg-RX-API-DMAC7.html)
JP2022527126A5 (cg-RX-API-DMAC7.html)
US20260131024A1 (en) Gene therapy for prader willi syndrome
US20240318198A1 (en) Gene therapy for angelman syndrome
AR129387A1 (es) Composiciones y métodos para el tratamiento de deficiencias auditivas no asociadas a la edad en un sujeto humano